As a global leader in the protection of public health, CSL Seqirus announced today that it is working to change the formulation of its influenza vaccine portfolio.
On February 8, 2024, Seqirus confirmed the B/Yamagata influenza virus strain will be removed from its influenza vaccines distributed in the United States, preferably in time for the 2024-2025 flu season.
The Centers for Disease Control and Prevention reported that over 157 million influenza vaccines were already distributed during the 2023-2024 flu season.
Read More
